Abstract
Purpose of review: This study will review the role of minimal residual disease (MRD) in predicting leukemia relapse following an allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML). Recent findings: PCR and multiparameter flow cytometry (MFC) assays are the most important methods of identifying MRD. PCR technique allows to recognize early genetic abnormalities of residual leukemic cells with high specificity and sensitivity. MFC assay using six-color to 10-color technology is an alternative option for MRD monitoring in AML patients without gene markers to detect leukemia-associated immunophenotype antigens (LAIPs). Summary: Despite the evidence that early detection of MRD after allogeneic HSCT is associated with a high risk of hematological relapse, it is still unclear whether this information can be translated into clinical practice, in order to prevent hematological relapse.
| Original language | English |
|---|---|
| Pages (from-to) | 381-387 |
| Number of pages | 7 |
| Journal | Current Opinion in Hematology |
| Volume | 18 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Nov 2011 |
Fingerprint
Keywords
- allogeneic hematopoietic stem cell transplant
- leukemia relapse
- minimal residual disease
ASJC Scopus subject areas
- Hematology
Cite this
Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. / Dominietto, Alida.
In: Current Opinion in Hematology, Vol. 18, No. 6, 11.2011, p. 381-387.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
AU - Dominietto, Alida
PY - 2011/11
Y1 - 2011/11
N2 - Purpose of review: This study will review the role of minimal residual disease (MRD) in predicting leukemia relapse following an allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML). Recent findings: PCR and multiparameter flow cytometry (MFC) assays are the most important methods of identifying MRD. PCR technique allows to recognize early genetic abnormalities of residual leukemic cells with high specificity and sensitivity. MFC assay using six-color to 10-color technology is an alternative option for MRD monitoring in AML patients without gene markers to detect leukemia-associated immunophenotype antigens (LAIPs). Summary: Despite the evidence that early detection of MRD after allogeneic HSCT is associated with a high risk of hematological relapse, it is still unclear whether this information can be translated into clinical practice, in order to prevent hematological relapse.
AB - Purpose of review: This study will review the role of minimal residual disease (MRD) in predicting leukemia relapse following an allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML). Recent findings: PCR and multiparameter flow cytometry (MFC) assays are the most important methods of identifying MRD. PCR technique allows to recognize early genetic abnormalities of residual leukemic cells with high specificity and sensitivity. MFC assay using six-color to 10-color technology is an alternative option for MRD monitoring in AML patients without gene markers to detect leukemia-associated immunophenotype antigens (LAIPs). Summary: Despite the evidence that early detection of MRD after allogeneic HSCT is associated with a high risk of hematological relapse, it is still unclear whether this information can be translated into clinical practice, in order to prevent hematological relapse.
KW - allogeneic hematopoietic stem cell transplant
KW - leukemia relapse
KW - minimal residual disease
UR - http://www.scopus.com/inward/record.url?scp=80054717409&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054717409&partnerID=8YFLogxK
U2 - 10.1097/MOH.0b013e32834bac7d
DO - 10.1097/MOH.0b013e32834bac7d
M3 - Article
C2 - 21986564
AN - SCOPUS:80054717409
VL - 18
SP - 381
EP - 387
JO - Current Opinion in Hematology
JF - Current Opinion in Hematology
SN - 1065-6251
IS - 6
ER -